Halozyme Therapeutics — May 11, 2026 release

For the full year 2026, the Company expects: • Total revenue of $1.710 billion to $1.810 billion, representing growth of 22% to 30% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API. • Revenue from royalties of $1.130 billion to $1.170 billion, representing growth of 30% to 35% over 2025. • Adjusted EBITDA of $1.125 billion to $1.205 billion, representing growth of 71% to 83% over 2025, including new Hypercon™ and Surf Bio investment of approximately $60 million. • Non-GAAP diluted earnings per share of $7.75 to $8.25, representing growth of 87% to 99% over 2025. The Company’s earnings per share guidance includes new Hypercon™ and Surf Bio investment of approximately $60 million and does not consider the impact of potential future share repurchases. Table 1. 2026 Financial Guidance   Guidance Range Total Revenue $1.710 to $1.810 billion Royalty Revenue $1.130 to $1.170 billion Adjusted EBITDA 1 $1.125 to $1.205 billion Non-GAAP Diluted EPS 1 $7.75 to $8.25 1     EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. Reconciliations between GAAP reported and Non-GAAP financial information for actual results are provided at the end of this earnings release. Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the first quarter ended March 31, 2026 today, Monday, May 11, 2026, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-regist